Baseline risk factors associated with immune related adverse events and atezolizumab

Baseline risk factors associated with immune related adverse events and atezolizumab

BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer patients in the last decade, but immune-related adverse events (irAEs) pose significant clinical challenges. Despite advances in the management of these unique toxicities, there remains an unmet need to further...

Full description

Bibliographic Details
Main Authors: Katrin Madjar, Rajat Mohindra, Gonzalo Durán-Pacheco, Rashad Rasul, Laurent Essioux, Vidya Maiya, G. Scott Chandler
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
immune checkpoint inhibitor
anti-PDL1
toxicity
immune-related adverse event
baseline risk factors
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1138305/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1138305/full

Similar Items